Bvf Partners L. P/Il Acquires 783,709 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) Stock

Posted by Defense World Staff on Nov 5th, 2023

Repare Therapeutics Inc. (NASDAQ:RPTX – Get Free Report) major shareholder Bvf Partners L. P/Il purchased 783,709 shares of Repare Therapeutics stock in a transaction that occurred on Thursday, November 2nd. The stock was acquired at an average price of $3.60 per share, for a total transaction of $2,821,352.40. Following the transaction, the insider now directly owns 4,662,402 shares of the company’s stock, valued at approximately $16,784,647.20. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Repare Therapeutics Stock Up 5.2 %

NASDAQ RPTX opened at $3.81 on Friday. The company has a fifty day moving average of $8.24 and a two-hundred day moving average of $9.59. The firm has a market capitalization of $160.36 million, a price-to-earnings ratio of -25.40 and a beta of 0.09. Repare Therapeutics Inc. has a 52 week low of $3.08 and a 52 week high of $18.68.

Repare Therapeutics (NASDAQ:RPTX – Get Free Report) last posted its quarterly earnings data on Wednesday, August 9th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.55. The company had revenue of $30.25 million during the quarter, compared to analyst estimates of $7.28 million. Repare Therapeutics had a negative net margin of 1.85% and a negative return on equity of 1.14%. Equities research analysts anticipate that Repare Therapeutics Inc. will post -2.46 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. HC Wainwright reduced their price target on shares of Repare Therapeutics from $26.00 to $25.00 and set a “buy” rating on the stock in a research report on Thursday, August 17th. Piper Sandler reduced their price target on shares of Repare Therapeutics from $30.00 to $25.00 and set an “overweight” rating on the stock in a research report on Monday, October 16th. Finally, Stifel Nicolaus boosted their price target on shares of Repare Therapeutics from $16.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, September 25th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.80.

Get Our Latest Report on Repare Therapeutics

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Versant Venture Management LLC purchased a new stake in shares of Repare Therapeutics during the second quarter valued at $28,002,000. Bank of America Corp DE boosted its stake in shares of Repare Therapeutics by 1,913.0% during the fourth quarter. Bank of America Corp DE now owns 260,886 shares of the company’s stock valued at $3,838,000 after purchasing an additional 247,926 shares during the period. Sio Capital Management LLC purchased a new stake in shares of Repare Therapeutics during the first quarter valued at $2,249,000. CHI Advisors LLC boosted its stake in shares of Repare Therapeutics by 7.1% during the first quarter. CHI Advisors LLC now owns 2,997,939 shares of the company’s stock valued at $29,500,000 after purchasing an additional 197,813 shares during the period. Finally, Affinity Asset Advisors LLC boosted its stake in shares of Repare Therapeutics by 72.5% during the first quarter. Affinity Asset Advisors LLC now owns 468,905 shares of the company’s stock valued at $6,677,000 after purchasing an additional 197,127 shares during the period. 85.09% of the stock is owned by hedge funds and other institutional investors.

About Repare Therapeutics

(Get Free Report)

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.